Mean Reduction In Foveal Thickness After Four Weeks Of Injection Bevacizumab (Avastin) Intravitreally For The Management Of Diabetic Macular Edema
Fatima Mehmood1, Waqas Asghar2, Uzma Hamza3, Maqbool Ahmed Jamali4, Qasim Lateef Chaudhry5, Imran Manzoor6.
Abstract: Aim: To determine the mean reduction in foveal thickness after 4 weeks of Intravitreal Bevacizumab (Avastin) for the management of diabetic macular edema Patients and methods: This Quasi experimental study included 95 eyes of 95 patients, which were diagnosed with diabetic macular edema, and treated between November 2016 and May 2017 at Ophthalmology department of Jinnah Hospital, Lahore. The aim and procedure of study was explained and informed consent was taken from all patients. A detailed history and ocular examination in these cases was done. Basic ophthalmological examination was done. The macular thickness was assessed one week before procedure by OCT (Zeiss 4000). Injection Bevacizumab (avastin) 1.25mg/0.05 ml was given intravitreally under topical anesthesia 3.5-4mmaway from limbus by researcher herself. After 4 weeks of injection, OCT was done on all patients and the outcome was decided on the modulation in thickness of of central maculi, which was recorded by the researcher herself. Results: The mean pre-procedure central macular thickness was 387.11+18.07 µm which reduced to 318.75+18.87 µm at 4 weeks after treatment, the mean decrease was recorded as 68.36+7.60 µm; p value was 0.0001, showing a significant difference. Conclusion: The mean reduction in foveal thickness after 4 weeks of Intravitreal Bevacizumab (Avastin) for the management of diabetic macular edema is significantly different as compared with pre-treatment macular thickness.
Keywords: Diabetic macular edema, Central macular thickness, Intravitreal Bevacizumab (Avastin), Mean decrease.